Boston Scientific Posts Strong Results for Q4 2023
Boston Scientific announced its fourth quarter and full year 2023 results the morning of Wednesday, January 31. The company’s revenue for the quarter rose 15% from $3.2 billion during Q4 2022, to $3.7 billion. For the full year 2023, the company generated net sales of $14.2 billion, growing 12% over the $12.7 billion generated during full year 2022. For Q1 2024, Boston Scientific expects sales to increase 7% to 9% on an organic basis. The company’s first-quarter sales guidance is impressive as its stock hit a record high. Boston Scientific’s stock jumped a little more than 3% from $61.43 to $63.47 in afternoon trades on the stock market the day of the announcement. ... Read More »
Boston Scientific Buys Claret Medical
The deals keep coming from Boston Scientific Corp. (NYSE: BSX). The medical device maker announced its sixth deal so far this year on July 20. The latest target is privately held Claret Medical, Inc., based in Santa Rosa, California. Claret developed and commercialized the Sentinel Cerebral Embolic Protection System, which is used to protect the brain during certain interventional procedures, primarily during transcatheter aortic valve (TAV) replacement. It is the only device to protect patients against the risk of stroke. The Sentinel System received CE Mark in 2014 and FDA clearance in 2017. Boston Scientific agreed to pay $220 million in cash, as well as a potential reimbursement-based... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
